Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common
vision-threatening complication and often affects adults of working age. Intravitreal
injection of any anti-vascular endothelial growth factor (VEGF) drugs would significantly
suppress the activity of the CNV and finally improve the visual acuity. However, more than
half of the patients would need one or more further injection for the recurrence or
uncontrolled with 1+pro re nata (PRN) treatment within one year, and whether increasing the
initial loading of intravitreal injection of anti-VEGF would be more efficacy for the
controlling the PM-CNV remained unknown.
Phase:
N/A
Details
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University